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Cancer stem cells (CSCs) are considered as responsible for initiation, maintenance and recurrence of solid tumors, thus
representing the key for tumor eradication. The antitumor activity of extracellular vesicles (EVs) derived from different stem cell
sources has been investigated with conflicting results. In our study, we evaluated, both in vitro and in vivo, the effect of EVs
derived from human bone marrow mesenchymal stromal cells (MSCs) and from a population of human liver stem cells (HLSCs)
of mesenchymal origin on renal CSCs. In vitro, both EV sources displayed pro-apoptotic, anti-proliferative and anti-invasive
effects on renal CSCs, but not on differentiated tumor cells. Pre-treatment of renal CSCs with EVs, before subcutaneous
injection in SCID mice, delayed tumor onset. We subsequently investigated the in vivo effect of MSC- and HLSC-EVs systemic
administration on progression of CSC-generated renal tumors. Tumor bio-distribution analysis identified intravenous treatment
as best route of administration. HLSC-EVs, but not MSC-EVs, significantly impaired subcutaneous tumor growth by reducing
tumor vascularization and inducing tumor cell apoptosis. Moreover, intravenous treatment with HLSC-EVs improved metastasis-
free survival. In EV treated tumor explants, we observed both the transfer and the induction of miR-145 and of miR-200 family
members. In transfected CSCs, the same miRNAs affected cell growth, invasion and survival. In conclusion, our results showed
a specific antitumor effect of HLSC-EVs on CSC-derived renal tumors in vivo, possibly ascribed to the transfer and induction of
specific antitumor miRNAs. Our study provides further evidence for a possible clinical application of stem cell-EVs in tumor
treatment.
Introduction
Renal cell carcinoma (RCC) is a common solid tumor, the
third among urogenital malignancies, and appears one of the
fastest increasing cancers in the last 10 years.1 RCC is often
associated with high recurrence with frequent metastatic
spread, leading to high mortality.2 In addition, RCC is resis-
tant to common chemotherapeutic drugs, while the response
to tyrosine kinase inhibitors is impaired within time by the
selection of a resistant population.3 Indeed, cancer stem cells
(CSCs) are now considered the responsible for the initiation,
maintenance and recurrence of solid tumors.4 In RCC, a CSC
population with stem-like properties has been identified by
several groups,5 by expression of different functional and sur-
face markers, including endoglin (CD105).6 In addition, renal
CSCs express mesenchymal markers, such as CD44, CD90,
CD146, CD73, CD29, vimentin and embryonic stem cells
markers such as Nanog, Oct4, Musashi, Nestin and Pax2
whereas they lack the expression of epithelial differentiation
markers.6
Targeting of renal CSCs represents an important approach
to eradicate RCC, considering their high drug resistance and
tumor-initiating capability. Extracellular vesicles (EVs) play a
key role in cell communication by transferring mRNAs,
microRNAs (miRNAs), lipids and proteins to target cells.7–9
In particular, stem cell-derived EVs are known to reprogram
target cells and promote tissue repair by transferring their
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cargo.9 However, their role in tumor development has been
controversial. In particular, mesenchymal stromal cells (MSCs)
derived EVs may display pro and antitumor effects.10 Recently,
EVs derived from human liver stem cells (HLSCs), another
source of human resident mesenchymal stromal cells isolated
from the liver, showed an anti-angiogenic effect on renal
tumor-derived endothelial cells, both in vitro and in vivo.11
Interestingly, MSC-EVs did not share the in vitro and in vivo
anti-angiogenic effect of HLSC-EVs, possibly due to a specific
miRNA signature,12 including differential expression of anti-
angiogenic miRNAs (miR-15a, miR-181b, miR-320c and miR-
874).11 Moreover, HLSC-EVs induced in vitro apoptosis of
renal CSCs, alone and in synergy with tyrosine kinase inhibi-
tors.13 However, no studies at present evaluated the effect of
stem cell-derived EVs on RCC and/or renal CSCs in vivo. In
our study, we aimed to dissect the effect of a systemic HLSC-
EV treatment in vivo on renal CSC-induced tumors, and we
correlated their antitumor activity with EV cargo.
Materials and Methods
Renal CSCs and RCC isolation and culture
Renal CSCs and RCC were isolated and characterized as pre-
viously described.6,14 Briefly, cells were obtained from speci-
mens of renal cell carcinomas from patients undergoing
radical nephrectomy according to the Ethics Committee of the
S. Giovanni Battista Hospital of Torino, Italy (168/2014).
CSCs were isolated from the total RCC population, using
anti-CD105 Ab by magnetic-activated cell sorting (MACS)
system (Miltenyi Biotec, Auburn, CA). CD105 positive CSCs
were cultured in the presence of the expansion medium, con-
sisting of DMEM LG (Invitrogen, Carlsbad, CA), with
insulin–transferrin–selenium, 10−9 M dexamethasone, 100 U
penicillin, 1,000 U streptomycin, 10 ng/ml EGF (all from
Sigma-Aldrich, St. Louis, MO) and 5% fetal calf serum (FCS;
Euroclone, MI, Italy). For cell cloning, single cells were seeded
in 96-well plates in the presence of the expansion medium. A
G7 and a D2 CD105 positive clonal renal cell carcinoma stem
cell line was selected and used for all the experiments. Total
RCC population was maintained in culture in DMEM LG
(Invitrogen), and 10% fetal calf serum (FCS) (Euroclone).
Mycoplasma absence in primary cells in the study was rou-
tinely tested using RT-PCR.
HLSCs and MSCs culture
HLSCs were isolated from human cryopreserved normal
hepatocytes obtained from Lonza (Basel, Switzerland), charac-
terized and cultured as previously described.15–18 Human
hepatocytes were plated in the presence of alfa minimum
essential medium/endothelial cell basal medium (expansion
media: α-MEM/EBM in the ratio 3:1, Lonza), supplemented
with antibiotics (100 U penicillin and 1,000 U streptomycin;
both from Sigma-Aldrich) and 10% Fetal Calf Serum (FCS,
Euroclone). After 2 weeks, HLSC colonies were expanded.
HLSC expressed several mesenchymal markers and, at vari-
ance with oval liver cells, did not express c-kit, CD34 and
cytokeratin 19 and showed multiple differentiative abilities.15
MSCs, that represent a mesoderm derived population of pro-
genitors, were obtained from Lonza and cultured and charac-
terized as previously described.19 MSCs were used up to the
sixth passage of culture. Mycoplasma absence in primary cells
in the study was routinely tested using RT-PCR.
EVs isolation and characterization
The supernatant of HLSCs or MSCs, cultured overnight in
serum-free media, was recovered and centrifuged for 20 min
at 3,000g and submitted to microfiltration (0.22 μm filter,
Merck-Millipore, Burlington, MA) to remove cell debris and
apoptotic bodies. Then, supernatants were submitted to ultra-
centrifugation at 100,000 g for 2 hr at 4C (Beckman Coulter
Optima L-90K, Fullerton, CA). Both HLSC-EVs and MSC-
EVs were resuspended in RPMI supplemented with 1%
dimethyl sulfoxide (DMSO, Sigma-Aldrich) and stored at
−80C for later use. Concentration and size distribution of
EVs were determined by the Nanosight LS300 system
(Malvern Panalytical, Malvern, UK). Briefly, EV preparations
were diluted (1:200) in sterile saline solution and analyzed by
the Nanoparticle Analysis System using the NTA 1.4 Analyti-
cal Software (Supporting Information Fig. S1a).13 EV purity
was assessed as ratio of n. EV/microgram protein.20 Electronic
microscopy was performed as previously described.12 More-
over, HLSC-EVs were characterized by Guava analysis
(Merck-Millipore) for the expression of exosomal markers
CD63 and CD81 and the markers of cells of origin CD44 and
CD29 (all from Beckton Dickinson, Franklin Lakes, NJ;
Supporting Information Fig. S1b). FITC and PE mouse non-
immune Isotypic IgG (Beckton Dickinson) served as controls.
EVs were incubated with each antibody, or isotype control
What’s new?
Stem cell-derived extracellular vesicles (EVs) can reprogram target cells and promote tissue repair by transferring their cargo.
However, the anti-tumor activity of EVs derived from different stem cell sources has been investigated with conflicting results.
Here, the authors demonstrate for the first time the anti-tumor effect of EVs from human liver stem cells (HLSC-EVs) in a
systemic intravenous administration model. HLSC-EVs had a selective effect on cancer stem cells that could be ascribed to the
transfer and induction of anti-tumor miRNAs. This study highlights the potential clinical use of stem cell-derived EVs, alone or
in combination with other cancer therapies.
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antibody at 4C in 100 μl PBS (Lonza) containing 0.1% bovine
serum albumin, and analyzed. All samples were gated on the
basis of negative controls and compensated appropriately
prior to analyses. The characteristics of HLSC-EVs are similar
to those described for EVs derived by MSC.21 For bio-
distribution experiments, MSC-EVs and HLSC-EVs were
labeled during ultracentrifugation with 1 μM Vybrant Cell
Tracers DiD fluorescent dye (TermoFisher Scientific, Wal-
tham, MA) as previously described.19 Labeled EVs were there-
fore washed twice by ultracentrifugation in PBS (Lonza).
Proliferation
For proliferation assay, cells were plated at a concentration of
1,500 renal CSCs/well, in a 96-multiwell plate and cultured
with different doses of HLSC-EVs or MSC-EVs (5, 10 or
50 × 103 EV/target cell). DNA synthesis was detected after
48 hr as incorporation of 5-bromo-2-deoxyuridine (BrdU)
using an enzyme-linked assay kit (Chemicon, Fisher Scientific,
Hampton, NH). Data are expressed as the mean  SD of the
mean of absorbance of at least three different experiments,
normalized to control (not treated cells).
Apoptosis
Cytofluorimetric evaluation of apoptotic cells was performed
using the Muse™ Annexin V & Dead Cell Kit (Merck-Mil-
lipore), according to the manufacturer’s recommendations.
Briefly, 25 × 103 cells were incubated with 50 × 103 HLSC-
EVs/target cells for 48 hr. Cells were then detached and
resuspended in Muse™ Annexin V & Dead Cell Kit, and the
percentage of apoptotic cells (Annexin V +) was detected. The
assay utilizes Annexin V to detect phosphatidylserine on the
external membrane of apoptotic cells. A dead cell marker
(7-AAD) is also used as an indicator of cell membrane struc-
tural integrity.
Invasion
Invasion was evaluated in 24-well cell culture inserts (Beckton
Dickinson) with a porous membrane (8.0 μm pore size) pre-
coated with 100 μg Matrigel per well as previously described.22
Briefly, 50 × 103 renal CSCs were plated in the presence of
5, 10 or 50 × 103 HLSC-EVs or MSC-EVs/target cell in the
upper side of the precoated transwell in DMEM (Euroclone).
As attractive stimulus, complete culture medium was added in
the well. After 48 hr, cells that moved from the upper side to
the lower one of the transwell were fixed in MetOH and sta-
ined with crystal violet (Sigma-Aldrich). Total area of invaded
Matrigel (magnification: 100×) was evaluated by ImageJ at
least five pictures per transwell.
Sphere formation
To grow renal CSCs in nonadhesive condition as floating
spheres, cells were plated at 1 × 105 cells/ml in serum-free
DMEM-F12 (Cambrex BioScience, Charles City, IA), sup-
plemented with 10 ng/ml bFGF, 20 ng/ml EGF, 5 μg/ml
insulin and 0.4% bovine serum albumin (all from Sigma-
Aldrich), as described,5,13,14 in the presence of 10 or 50 × 103
HLSC-EVs or MSC-EVs/target cell for 72 hr. Sphere viability
was then measured by MTT (3-(4,5-dimetiltiazol-2-yl)-
2,5-difeniltetrasodium bromide, Merck-Millipore), as previ-
ously described.23 Briefly, spheroids were centrifuged and
resuspended in 300 μl of PBS solution for efficient disaggrega-
tion. Spheroid-derived cells were then plated in 96-well plates
in triplicates and analyzed according to manufacturer’s
instructions. Data are expressed as mean  SD of the mean
absorbance of three different experiments performed in tripli-
cates and normalized to untreated cells.
In vivo subcutaneous model of CSC-derived renal tumor
All animal studies were conducted in accordance with the
national guidelines and regulations and were approved by the
Ethics Committee of the University of Torino (Protocol Num-
ber: 338/2016-PR). In order to evaluate the effect of HLSC-
EVs on renal CSCs tumor growth, renal CSCs were implanted
subcutaneously into SCID mice (Charles River, Wilmington,
MA) within growth factor-reduced Matrigel (Beckton Dickin-
son). Briefly, 1 × 103 renal CSCs were resuspended in 75 μl
DMEM plus 125 μl of Matrigel at 4C and immediately
injected subcutaneously SCID mice. Two plugs/mouse was
performed. In pretreatment experiments, cells were treated
with 50 × 103 HLSC-EVs or MSC-EVs/target cell for 24 hr
prior to cell injection. In treatment experiments, mice were
treated intravenously with HLSC-EVs (1 × 1010 EVs/mouse/
injection) or PBS twice per week for 4 weeks, starting 1 week
after cell injection. Tumors were measured with a caliper once
per week. Five weeks after cell injection, mice were sacrificed,
plugs recovered and processed for histological and molecular
analysis. Isolation of CD105+ CSCs from plugs was performed
using the magnetic-activated cell sorting (MACS) system
(Miltenyi Biotec, Auburn, CA).
Tunel assay (ApopTag Apoptosis Detection Kit; Merck
Millipore) was performed on paraffin-embedded sections in
order to evaluate renal tumor cell apoptosis in recovered
plugs, following the manufacturer’s instructions. The amount
of apoptotic cells was evaluated by counting the number of
Tunel positive cells per field in 10 randomly chosen fields per
tumor section (magnification: 400×) using ImageJ software.
Optical imaging and biodistribution of EVs
SCID mice were subcutaneously with 1 × 103 renal CSCs
within Matrigel. After 3 weeks, mice were treated with 1.5
× 1010 labeled EVs/mouse (MSC- and HLSC-EVs), using two
different routes of EV administration to compare tumor EV
localization. Mice were sacrificed at different time points
(5, 24 and 48 hr post-EV administration) and dissected
tumors were subjected to Optical Imaging (n = 3 per EV type,
administration route and time point). All studies were per-
formed with IVIS 200 small animal imaging system
(PerkinElmer, Waltham, MA) using excitation filter at
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640 nm and an emission filter at 700 nm. Fluorescence emis-
sion was normalized to photons per second per centimeter
squared per steradian (p/sec/cm2/sr) as previously described.19
The fluorescence signal was quantified in tumors in ROI draw
freehand. The relative mean fluorescence intensity of each
ROI was obtained by subtracting the mean fluorescence inten-
sity of the corresponding ROI of the fluorescence intensity of
mice not treated with labeled EVs. Data were expressed as the
average radiance  SD. Images were acquired and analyzed
using Living Image 4.0 software (Perkin Elmer).
Generation of luciferase-expressing CSCs (LUC-CSCs)
Renal CSCs were infected with a lentivirus containing the
pBMN(CMV-copGFP-Luc2-Puro) plasmid (Addgene plasmid
# 80389).24 Briefly, 293T cells were transfected with constructs
using ViraPower Packaging Mix (Life Technologies, Carlsbad,
CA) for lentiviruses production, according to manufacturer’s
instructions. After titering the lentiviral stock, renal CSCs
were infected with lentiviral particles following the manufac-
turer’s instructions. Cells were selected by puromycin (Gibco,
Thermofisher; 1 μg/ml) and, after 1 week, antibiotic-resistant
cells were expanded. Cell infection was considered effective
when the percentage of GFP positive cells was >95%, as
assessed by cytofluorimetric analysis (data not shown). Firefly
luciferase expression on renal CSCs was assessed by IVIS
200 small animal imaging system (PerkinElmer) by incubating
20 μg D-Luciferin (PerkinElmer) in 100 μl complete medium
containing different cell numbers (1 × 102–1 × 106). Cells
were considered effectively expressing luciferase when the sig-
nal of 1 × 103 cells was detected (data not shown).
Hematogenous CSCs spread to the lungs
Hematogenous CSCs spread to the lungs was induced in SCID
mice (Charles River) by injecting 5 × 105 LUC-CSCs in the
tail vein. One week after cell injection, mice were treated
intravenously with HLSC-EVs or PBS twice per week for
4 weeks. The formation of lung tumor colonies was monitored
weekly with IVIS 200 small animal imaging system
(PerkinElmer). Images were acquired whole body and ana-
lyzed using Living Image 4.0 software (PerkinElmer).25 Briefly,
mice were anesthetized by isoflurane inhalation and then
injected intraperitoneally with 3 mg D-luciferin (PerkinElmer).
Ten minutes after injection, bioluminescent data were col-
lected with an imaging time of 3 min.
The luminescence was quantified in the region of interest
(ROI) draw freehand. A mouse was considered positive for
lung tumor formation when luminescence values were at least
3.5 times higher than mice not bearing lung tumor foci. Data
were expressed as average radiance  SD.
mRNA and miRNA isolation and real-time PCR
Total RNA was isolated from different preparations using
Trizol Reagent (Ambion, Thermofisher) according to the
manufacturer’s protocol. RNA was then quantified
spectrophotometrically (Nanodrop ND-1000, Thermofisher).
For gene expression analysis, quantitative Real-time PCR was
performed. Briefly, first-strand cDNA was produced from
200 ng total RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) or,
for miRNA analysis, the miScript Reverse Transcription Kit
(Qiagen, Hilden, Germany). Real-time PCR experiments were
performed in 20 μl reaction mixture containing 5 ng of cDNA
template, the sequence-specific oligonucleotide primers (pur-
chased from MWG-Biotech, Nantes, BRU, Luxembourg) and
the Power SYBR Green PCR Master Mix (Applied Bio-
systems), or miScript SYBR Green PCR Kit (Qiagen). TBP
mRNA, or RNU48 were used to normalize mRNA or miRNA
inputs, respectively. The sequence-specific oligonucleotide
used for mRNA analysis is TBP Fw: 50-TGT GCA CAG GAG
CCA AGA GT-30; Rev: 50-ATT TTC TTG CTG CCA GTC
TGG-30; C-MYC Fw: 50-CAG CGA CTC TGA GGA GGA
ACA-30; Rev: 50-TGA GGA GGT TTG CTG TGG C-30; EGFR
Fw: 50-GTG ACC GTT TGG GAG TTG ATG A-30; Rev:
50-GGC TGA GGG AGG CGT TCT C-30; ZEB1 Fw: 50-GAA
GAG ATC AAA GAC ATG TGA CGC-30; Rev: 50-TCT CCA
CTG TGA ATT CTT AAG TGC TC-30; ZEB2 Fw: 50-CCA
CGA TCC AGA CCG CA-30; Rev: 50-GTA CTC CTC GAT
GTC GAC TGC A-30; MMP1 Fw: 50-CCA ACA ATT TCA
GAG AGT ACA ACT TAC AT-30; Rev: 50-TGA AGG TGT
AGC TAG GGT ACA TCA AA-30. The Fw sequence-specific
oligonucleotide used for miRNA analysis are hsa-miR-24-3p:
50-TGG CTC AGT TCA GCA GGA A-30; hsa-miR-29a-3p:
50-TAG CAC CAT CTG AAA TCG GTT-30; hsa-miR-31-5p:
50-AGG CAA GAT CCT GGC ATA G-30; hsa-miR-Let7b-5p:
50-TGA GGT AGT AGG TTG TGT GGT T-30; hsa-miR-
141-3p: 50-TAA CAC TGT CTG GTA AAG ATG G-30; hsa-
miR-145-5p: 50-GTC CAG TTT TCC CAG GAA TCC-30;
hsa-miR-200a-3p: 50-TAA CAC TGT CTG GTA ACG ATG
T-30; hsa-miR-200b-3p: 50-TAA TAC TGC CTG GTA ATG
ATG A-30; hsa-miR-200c-3p: 50-ACT GCC GGG TAA TGA
TGG A-30; hsa-miR-223-3p: 50-TGT CAG TTT GTC AAA
TAC CCC A-30; hsa-miR-429: 50-TAA TAC TGT CTG GTA
AAA CCG T-30; hsa-miR-451a: 50-AAA CCG TTA CCA TTA
CTG AGT T-30; RNU-48: 50-AAC TCT GAG TGT GTC GCT
GAT G-30.
Cell transfection
Transfection of renal CSCs was performed using HiPerfect
reagent (Qiagen) as previously described.12 Briefly, 1 × 105
renal CSCs/well were plated in a 12-well plate and left adhere
overnight. The day after, medium was replaced with 1 ml
DMEM containing 10 μl HiPerfect reagent (Qiagen) and
100 pmol of the specific mimic miRNAs (all from Qiagen).
The day after transfection fresh growth medium was replaced
and on Day 2, the cells were used for in vitro experiments
(proliferation, apoptosis and invasion assay) or gene expres-
sion analysis (Real-time PCR). Cells transfected with scramble
mimic (Qiagen) were used as control.
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Transcription inhibition with α-Amanitin
Renal CSCs were seeded in six-well plate (2 × 105/well) and
left to adhere overnight. The next day, cells were incubated
with the transcriptional inhibitor, α-Amanitin (50 μg/ml,
Sigma-Aldrich, St. Louis, MO) either in the absence or in the
presence of 5 × 104 HLSC-EVs/target cell. Cells were collected
for RNA extraction and real-time PCR analysis 1, 3 or 6 hr
after.
Statistical analysis
Statistical analysis was performed by using the Student t-test
or ANOVA with Dunnet’s multicomparison tests, as appro-
priate. A value of p < 0.05 was considered significant. All sta-
tistical analyses were carried out on Graph Pad Prism version
5.04 (Graph Pad Software, Inc, La Jolla, CA).
Data availability
The experimental data that support the findings of our study
are available from the corresponding author upon reasonable
request.
Results
Stem cell-derived EVs reduce proliferation, sphere formation
and invasion of renal CSCs
We recently showed that EVs from HLSCs induced renal
CSCs apoptosis.13 In order to extend the effect of HLSC-EVs
to in vivo treatment, we first tested their effect on prolifera-
tion, sphere formation and invasion ability of two different
renal CSC lines, and compared their effect with that of bone
marrow-derived MSC-EVs, a mesoderm derived population of
progenitors. Stem cell-derived EVs were isolated by ultracen-
trifugation and characterized as previously described.11,13 Sim-
ilar size and distribution of MSC- and HLSC-EVs were
assessed by NanoSight analysis and by electron microscopy
(Supporting Information Fig. S1a). Moreover, by cyto-
fluorimetric Guava analysis, we found that both sources
expressed markers of exosomes and of the originating cells
(CD81, CD63 and CD29, CD105, CD73 respectively), while
the hematopoietic marker CD45 was not detectable
(Supporting Information Fig. S1b). As reported,13 HLSC-EVs,
but not MSC-EVs, displayed a proapoptotic effect on renal
CSCs (Supporting Information Fig. S1c). Moreover, EVs from
both stem cell sources impaired proliferation of renal CSCs
obtained from two different RCC samples in a dose-
dependent manner (Fig. 1a). In addition, they significantly
reduced the capability of renal CSCs to form spheres, a char-
acteristic ability of CSCs (Fig. 1b) and significantly limited
their invasion ability (Figs. 1c and 1d).
To evaluate the possible activity of stem cell-derived EVs
on differentiated tumor cells in vivo, we isolated renal tumor
cells from surgical specimens deriving from 17 RCC patients
(summarized in Fig. 2). Cells were characterized for the
expression of EPCAM, Cytokeratin and Vimentin, in compar-
ison with the tumor of origin (Figs. 2a and 2b). Stem
cell-derived EVs significantly affected primary tumor cell
invasion, whereas no significant activity was present on tumor
cell proliferation or apoptosis (Figs. 2c–2f; >20% apoptosis in
3/17 patients).
HLSC-EV pretreatment induced a delay in tumor onset
We subsequently generated RCC tumors in SCID mice by
subcutaneous injection of 1,000 renal CSCs. Recovery of
tumor cells after 28 days showed the presence of CD105 posi-
tive CSCs in a percentage ranging from 14.9% to 90.1% (mean
63.8  24.7; Supporting Information Fig. S2a). CD105 posi-
tive, but not CD105 negative cells, were able to generate sec-
ondary and tertiary tumors.6,13 In vitro apoptosis analysis of
recovered cells exhibited an effect of HLSC-EVs on CD105
positive and not on CD105 negative cells, confirming the
selective effect of HLSC-EVs on renal CSCs (Supporting
Information Figs. S2b and S2c). We therefore analyzed the
effect of MSC- and HLSC-EVs on the subsequent generation
and development of RCC tumors (Fig. 3). CSCs were
pretreated or not for 24 hr with 50 × 103 MSC-EVs or HLSC-
EVs/target cells, the highest effective dose in the in vitro
experiments. As shown in Figure 3, pretreatment with both
MSC-EVs and HLSC-EVs delayed tumor onset of about
2 weeks (Fig. 3a). At sacrifice, however, no difference was
observed in tumor size among the groups (Fig. 3b). In addi-
tion, MSC-EV and HLSC-EV pretreatment did not reduce
angiogenesis in vivo (Fig. 3c).
Labeled EV biodistribution in CSCs tumors
In order to assess the EV tumor targeting in vivo, DiD labeled
EVs were injected in animals with established tumors. By
Optical Imaging, using IVIS technology, the fluorescence sig-
nals of labeled EVs were detected in all tumors as soon as
5 hr after administration (Figs. 3d and 3e). Intraperitoneal
and intravenous injections were compared to identify the best
route of administration for further in vivo experiments. For
both types of EVs (MSC-EVs and HLSC-EVs), intravenous
administration was the best option in which EVs show the
maximum accumulation within tumors. Localization reached
the pick after 24 hr; then the fluorescent signal started
decreasing (Fig. 3e). Using intraperitoneal injection, the accu-
mulation of labeled EVs within tumors was significantly lower
for both types of EVs (Fig. 3e).
HLSC-EV systemic administration reduced tumor growth
in vivo
On the base of the above results on biodistribution, we studied
the effect of MSC-EVs and HLSC-EVs on tumor growth using
the intravenous route of administration (i.v.). EVs (1 × 1010)
were administered when subcutaneous tumors were palpable
(10 days), twice a week for 4 weeks. As shown in Figure 4,
i.v. treatment with HLSC-EVs, but not MSC-EVs, induced a
significant reduction of tumor growth. The antitumor effect of
HLSC-EVs was statistically significant already starting from
1698 Clinical application of stem cell-EVs in tumor treatment


















Week 2 of treatment (Fig. 4a). Tumor size analysis after mice
sacrifice confirmed the tumor reduction exerted by HLSC-EVs
observed during the time of treatment (Fig. 4b). Moreover,
angiogenesis evaluation within tumors revealed a significant
reduction in red blood containing vessels in mice treated with
HLSC-EVs, but not MSC-EVs (Fig. 4c). This is consistent with
the antiangiogenic effect of HLSC-EVs but not MSC-EVs on
renal human tumor endothelial cells.12 Moreover, immunohis-
tochemistry for the detection of apoptosis, performed by
Tunel assay, showed a significant increase of apoptotic cells in
tumors of mice treated with HLSC-EVs but not MSC-EVs
(Fig. 4d).
HLSC-EV treatment decreased the hematogenous spread
to the lungs
In order to evaluate the role of HLSC-EVs in hematogenous
CSCs spread to the lungs, we i.v. injected in SCID mice a stable
luciferase-expressing renal CSCs clone and luciferase activity
Figure 1. In vitro effect of EVs on renal CSCs. (a) Proliferation levels, expressed as percentage, of two different renal CSCs clones (G7 and D2)
incubated with different doses (ranging from 5 (5k) to 50 (50k) × 103 EVs/target cells) of MSC- or HLSC-EVs. (b) Quantification of sphere
formation ability of renal CSCs stimulated with two different doses of MSC- and HLSC-EVs (10k and 50k EVs/target cell). (c) Representative
micrographs showing the reduction of renal CSCs invasion capacity induced by MSC- and HLSC-EVs treatment (50k/target cell). Original
magnification: 200×. (d) Quantification of EVs effect (5, 10 and 50k EVs/target cell) on renal CSCs invasion, represented as percentage of
invaded area. Data (a, b and c) are expressed as mean  SD of three different experiments, normalized to untreated renal CSCs (CTL).
*#p < 0.05 vs. CTL.
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was analyzed by Optical Imaging in order to monitor tumor
progression. Tumor colonies in lungs were detectable after
10 days (Fig. 4e). EVs were therefore administered from Day
10, twice a week for 4 weeks. The incidence of lung tumor
colonies was analyzed by IVIS. We calculated the lung tumor-
free survival with the Kaplan–Maier curve and the result, rep-
resenting all mice, showed a higher percentage of mice that did
not develop detectable CSCs colonies in the HLSC-EVs group
Figure 2. Effect of MSC- and HLSC-EVs on differentiated RCC cells. (a) Representative micrographs showing hematoxylin and eosin (EE) and
Periodic Acid Schiff (PAS) staining, and immunohistochemistry for Pan Cytokeratin (PanCK) and Vimentin of the isolated cells (CELLS)
compared to the tissue of origin (TISSUE). (b) Summary of the different RCC types used for cell isolation, and expression of the epithelial
marker EPCAM and of the endothelial marker CD31 evaluated by cytofluorimetric analysis (Score: +++ = >90%; ++ = >60%; + = >30%;
+/− = <10% positive cells; − = No detected expression). (c–e) Quantification of proliferation (C), apoptosis (D) and invasion (E) of RCC-
derived cells treated or not with different doses of EVs (1–50k = 1–50 × 103 EVs/target cell). Data are represented as mean  SD of at least
two experiments performed at least on two RCC/type, normalized to untreated cells (CTL). *p < 0.05 and **p < 0.001 vs. CTL.
(f ) Representative micrographs of invasion assay performed on two RCC/type. Original magnification: 200×.
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compared to the control group. At Week 3, about 51% of
HLSC-EV treated mice did not develop lung tumor foci with
respect to 15% of control mice (Figs. 4f and 4g).
HLSC-EV treatment induced the expression of antitumor
miRNAs
To understand if the antitumor effect observed after HLSC-
EVs treatment of renal CSCs tumors in vivo could be ascribed
to antitumor miRNAs carried or induced by EVs, we analyzed
the expression of a panel of antitumor miRNAs, known to be
downregulated in RCC,26 on renal CSCs-derived tumors
i.v. treated with PBS (CTL), MSC- or HLSC-EVs twice a week
for 4 weeks (Fig. 5). Interestingly, in renal CSCs-derived
tumors treated i.v. with HLSC-EVs, but not with MSC-EVs,
we observed a significant upregulation of the antitumor
miRNAs miR-Let7b, miR-200b, miR-200c and miR-223, and
a slight increase of miR-145 (Fig. 5a), confirming the effect on
tumor growth inhibition of HLSC-EVs, but not of MSC-EVs,
observed in vivo.
In parallel, we evaluated the expression of some targets of
the induced miRNAs, such as C-MYC (miR-145 target),
EGFR (miR-145 target), ZEB1 and ZEB2 (miR-200b and miR-
200c targets), and MMP1 (miR-145 and miR-200b target;
Fig. 5b). EGFR, ZEB2 and MMP1 were found downregulated
in HLSC-EVs treated tumors.
We also confirmed that these microRNAs are expressed at
low level in renal CSCs (Supporting Information Figs. S3a
and S3b). Indeed, the antitumor miRNAs were present at
Figure 3. In vivo tumor growth after CSCs pretreatment with EVs and EV tumor targeting. (a) Percentage of mice that did not develop tumor
after subcutaneous injection of renal CSCs pretreated with MSC- or HLSC-EVs, calculated with Kaplan–Meier curve. Data are expressed as
mean  SD of 12 tumors for each group (CTL, MSC-EVs and HLSC-EVs). (b) Graph showing tumor size (mm3) of recovered plugs.
(c) Representative images of tumors stained with Masson’s trichromic reaction. (d) Representative images by Optical Imaging of tumors
collected at 5 and 24 hr post-EV injection. IV: intravenous, IP: intraperitoneal. (e) Fluorescence intensity of dissected tumors measured as
Average Radiance  SD at 5, 24 and 48 hr of mice treated with MSC-EVs and HLSC-EVs. Background signal derived from tumors of untreated
mouse (n = 3) was subtracted; **p < 0.01 intravenous versus intraperitoneal injection.
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different levels in HLSC-EVs (Supporting Information
Fig. S3c). In particular, among the antitumor miRNAs
induced in vivo by HLSC-EV treatment, miR-145 and miR-
Let7b are present at high levels (CT < 30), while low levels of
miR-200b, miR-200c and miR-223 were detected in HLSC-
EVs (Supporting Information Fig. S3c). In order to evaluate
whether these miRNAs were transferred or induced by EV
treatment, we blocked cell transcription with α-Amanitin, as
Figure 4. Intravenous injection of HLSC-EVs reduced tumor growth and delayed CSCs lung spread. (a) Tumor size (mm3) of untreated mice
(CTL), and of mice i.v. treated with MSC- or HLSC-EVs during the experiment. (b) Tumor size (mm3) of recovered plugs after sacrifice.
(c) Evaluation of angiogenesis within plugs, expressed as number of vessels connected to mouse vasculature/field, and representative
images of vessels stained with Masson’s trichromic reaction. (d) Tumor apoptosis evaluation by Tunel assay, expressed as number of TUNEL
positive cells/field, and representative micrographs showing apoptosis within tumors. (a–d) Data are expressed as mean  SEM of n = 20
tumors for control group (CTL), n = 18 for HLSC-EVs group and n = 14 for MSC-EVs group. *p > 0.05 vs. CTL. (e) Representative micrographs
showing IVIS analysis of lung CSCs foci after 10 days from i.v. injection of renal CSCs; (f ) Kaplan–Meier curve showing the percentage of
mice that did not develop lung tumors during the time of experiment. Data are expressed as mean  SEM of 24 HLSC-EVs and 24 PBS treated
mice. *p = 0.0016. (g) Representative micrographs showing IVIS analysis of lungs at Week 3.
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previously described,11 and miRNA expression in renal CSCs
in vitro at different time points was evaluated. As shown in
Figure 5c, α-Amanitin abrogated the increase of miR-Let7b,
miR-200c and miR-200b induced by HLSC-EV treatment,
thus suggesting an EV mediated upregulation. On the con-
trary, renal CSCs treated with HLSC-EVs showed an early
increase of miR-145 levels, also in the presence of α-Amanitin,
suggesting a direct transfer of this miRNA. As a result of both
miR-transfer and induction, we observed a significant
downregulation in vitro of the specific targets EGFR, ZEB2,
and MMP1 (Fig. 5d), thus confirming our in vivo results.
In vitro antiproliferative, antiinvasive and proapoptotic
effect of antitumor miRNAs induced by HLSC-EVs
Finally, we analyzed the role of the identified antitumor miRNAs
induced by HLSC-EV treatment both in vitro and in vivo, by
transfecting renal CSCs with mimics for the panel of antitumor
miRNAs tested in the in vivo experiments. Transfection efficacy is
Figure 5. HLSC-EVs induce antitumor miRNA expression both in vivo and in vitro. (a) Antitumor miRNAs expression on renal CSCs-derived
tumors, evaluated by real-time PCR, after 4 weeks of EV-treatment. Data are expressed as mean  SD of Relative Quantification
(RQ) normalized to PBS-treated tumors (CTL) and to RNU6B of 10 CTL, 10 MSC- and 10 HLSC-EV treated tumors. **p < 0.001 vs. CTL. (b) Real-
time PCR analysis of antitumor miRNA targets in renal CSC-derived tumors i.v. treated for 4 weeks with HLSC-EVs (n = 10). Data are expressed
as mean  SD of Relative Quantification (RQ) normalized to PBS-treated tumors (CTL) and to TBP. **p < 0.001 vs. CTL. (c and d) Real-time PCR
analysis of renal CSCs treated with HLSC-EVs alone or in the presence of α-Amanitin for 1, 3 and 6 hr, showing the expression of miR-Let7b,
miR200b, miR-200c and miR-145 (c) and of their targets C-MYC, EGFR, ZEB2 and MMP1 (d). Data (c and d) are expressed as Relative
Quantification (RQ) of three different experiments, normalized to RNU6B or TBP and to untreated cells (CTL). *p < 0.05 and **p < 0.001 vs.
CTL; $p < 0.05 and $$p < 0.05 vs. HLSC-EVs.
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shown in Supporting Information Figure 3d. Transfection of renal
CSCs with mimics for miR-Let7b, miR-145, miR-200a, miR-200b,
miR-200c, miR-223 and miR-429 (red bars, Figs. 6a–6c) resulted
in a significant reduction of renal CSCs proliferative ability
(Fig. 6a). A significant induction of apoptosis was observed when
renal CSCs were transfected with mimics for miR-145, miR-200b
and miR-200c (Fig. 6b). In addition, we demonstrated a signifi-
cant anti-invasive effect of CSCs transfection with mimics for
miR-29a, miR-141, miR-145, miR-200b, miR-200c, miR-223,
miR-451 and miR-429 (Fig. 6c).
Co-transfection of CSCs with miR-145, that was directly
transferred by HLSC-EVs to CSCs, together with miR-200b and
miR-200c or with miR-Let7b and miR-223, whose expression in
CSCs was induced by HLSC-EVs treatment (Fig. 5), resulted in
a higher effect in respect with the single miR transfection on
proliferation, apoptosis and invasion (Figs. 6a and 6c).
We therefore demonstrated the anti-invasive, antiproliferative
and proapoptotic effects of selected miRNAs (Fig. 6d). Moreover,
three miRNAs showed antiproliferative, anti-invasive and apopto-
tic activity: miR-145, miR-200b and miR-200c. Interestingly, these
three miRNAs are those induced by HLSC-EVs treatment of
renal CSCs-derived tumors in vivo (Fig. 5a).
Discussion
In the present paper, we demonstrate that intravenous admin-
istration of EVs derived from a liver resident population of
mesenchymal stromal cells reduced development, growth and
improved lung tumor-free survival of a RCC obtained by
injection of renal CSCs. This effect was not shared by EVs
derived from bone marrow MSC. HLSC-EVs targeted the
tumor and induced transfer and upregulation of selected anti-
tumor microRNAs, able to affect CSC growth, invasion and
survival. Stem cell-derived EVs, and in particular MSC-EVs,
acquire increasing interest for their effect on tissue repair, lim-
iting inflammation and promoting restoration of injured tis-
sue.21 The role of stem cell-derived EVs on in vivo tumor
growth and progression is however debated, and appears
related to EV origin, to the tumor nature as well as to the
modality of EV treatment.27–31 For instance, tumor cell pre-
treatment with EVs from embryonic stem cells inhibited
breast and colorectal carcinoma development.28 Similarly,
Wharton Jelly MSC-EVs inhibited bladder carcinoma when
mixed with cells before their in vivo implantation.29 The
same Wharton Jelly MSC-EVs showed an opposite effect
when tested on renal carcinoma xenografts, increasing its
Figure 6. Transfection of renal CSCs with antitumor miRNAs. (a–c) Functional assays performed on transfected renal CSCs, showing the effect
of selected mimics on proliferation (a), apoptosis (b) and invasion (c) 72 hr after transfection. Data are expressed as mean  SD of three
independent experiments. *p < 0.05 and **p < 0.001 vs. CSCs transfection with scrambled sequences (SCR). (d) Schematic representation of
the functional effect of specific mimics.
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development.30 Data on bone marrow MSC-EVs are quite
contradictory as well.27 Indeed, pretreatment with bone mar-
row MSCs limited myeloma growth and promoted dormancy
of breast tumors,32,33 and subcutaneous injection of MSC-EVs
limited breast tumor angiogenesis.34 Moreover, intratumor
injection of bone marrow MSC-EVs limited tumor growth of
ovarian, hepatocellular carcinoma and Kaposi’s sarcoma.35
We also confirmed here that pretreatment of renal carcinomas
with bone marrow MSC-EVs delayed tumor formation,
although no difference was observed when tumor started to
grow exponentially. On the other side, pretreatment with bone
marrow MSC-EVs promoted myeloma, breast, gastric and
colon tumor growth and angiogenesis.36–39 Similarly, pre-
treatment with human umbilical cord MSC-EVs increased the
growth of lung adenocarcinoma.40 In the present paper, we
tested for the first time the use of stem cell-EVs in a systemic
intravenous administration on tumor growth. The results
showed the inefficacy of MSC-EV intravenous administration
whereas HLSC-EVs showed a consistent effect on CSC tumor
growth and lung tumor spread. The antitumor ability of EVs
from another source of tissue-resident stem cells, that is car-
diac stem cells, was recently reported using an intraperitoneal
administration.41 HLSC-EVs therefore appear an interesting
source of EVs with antitumor characteristics. HLSC-EVs were
previously reported to inhibit liver carcinomas after
intratumor injection, and to induce apoptosis of renal
CSCs.13,17 In this article, besides confirming the proapoptotic
effects of HLSC-EVs, we also found an effect on CSC invasion
and organization into spheres, a stem-related characteristic.
At variance, the effect of HLSC-EVs on differentiated primary
tumor cell lines isolated from renal carcinomas was restricted
to inhibition of invasion. This is different from the data
obtained in vivo showing the proapoptotic effect of HLSC-
EVs on the majority of cells of the tumor rather than on a
selected stem-related cell population. It can be therefore spec-
ulated that the observed in vivo effect could be dependent on
a combined action on the tumor cells as well as on the tumor
endothelium, confirmed by the reduction of angiogenesis.
Indeed, the effect of HLSC-EVs on renal tumor endothelial
cells has been recently detailed.11 The systemic administration
of EVs led to a rapid intratumor localization, as soon as 5 hr.
This was higher than that obtained with intraperitoneal injec-
tion, and could be related to the increased permeability of
tumor vessels and to intrinsic targeting characteristics. EVs
possess unique features in terms of targeting and natural
cargo/drug delivering. In fact, EVs, compared to synthetic
liposomes, display an excellent biological tolerance due to
their endogenous nature and an intrinsic ability to cross over
cellular and tissue barriers.42 Moreover, different types of EVs
show enhanced localization in specific tissues, and may be
used as selective delivery system.43 Furthermore, thanks to the
presence of adhesion surface molecules, EVs have the advan-
tage of rapid internalization.7 The uptake of HLSC-EVs by
tumor cells is also shown by the increase of miR-145, which is
highly expressed by HLSC-EVs. In addition, other antitumor
miRNAs were interestingly upregulated in EV treated tumors.
This appears related to induction of miRNAs by HLSC, as the
EVs themselves did not show high level of these miRNAs in
their cargo. Moreover, in vitro experiments using α-Amanitin
to inhibit de novo transcription clearly confirmed the rapid
upregulation of miR-145, but not of miR-200 family, indicat-
ing the absence of transfer from EVs. MiR-145 is a well-
known antitumor miRNA, downregulated in many solid
tumors, and it is involved in many steps of tumorigenesis. In
particular, miR-145 modulates oncogenes involved in prolifer-
ation, angiogenesis, CSCs differentiation and invasion.44 The
antitumor effect of miR-145 in RCC mainly involves the regu-
lation of genes orchestrating cell invasion.45–47 Interestingly,
renal CSCs transfection with a panel of antitumor miRNAs
confirmed in our model that miR-145 was active in blocking
CSCs invasion, proliferation and survival. Moreover, in renal
CSCs treated with HLSC-EVs, we observed both in vitro and
in vivo the downregulation of EGFR and MMP1, described as
direct miR-145 targets.48,49 In addition, HLSC-EVs induced
the transcription of miR-200b and miR-200c, members of the
miR-200 family, known to be downregulated in RCC.50
Likewise, we observed that transfection of renal CSCs with
miR-200b and miR-200c impaired renal CSCs functions.
HLSC-EVs not only increased miR-200 family but also
reduced their specific target ZEB2, one of the main regulators
of epithelial–mesenchymal transition. However, it cannot be
excluded that other molecular mechanisms may be involved
in the complex setting of the in vivo tumor growth. In particu-
lar, other EV cargo, such as proteins, lipids or RNA species as
well as modulation of other cell functions, such as activation
of signal transduction, or effects on cell metabolism, could
play a role in the observed antitumor effects on renal CSCs.
In conclusion, our results showed a specific antitumor
effect of HLSC-EVs, and not of MSC-EVs, on CSC-derived
renal tumors in vivo, that could be ascribed to the transfer
and induction of specific antitumor miRNAs. Our study pro-
vides further evidence on the clinical use of HLSC-EVs in
renal tumor treatment, by their possible administration alone
or in combination with the current therapies.
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